Bristol-Myers Squibb acquisition of IFM Therapeutics, and
Amgen-CytomX licensing deal recognized among more than 4,000
transactions in annual Cortellis Deal of the Year Awards from Clarivate
Analytics
PHILADELPHIA--(BUSINESS WIRE)--
The rapidly innovating immuno-oncology sector is transforming the cancer
treatment landscape, and the results of the Clarivate Cortellis 2017
“Deal of the Year” awards bear that out. Clarivate Analytics today
announced that Bristol Myers-Squibb’s acquisition of IFM Therapeutics,
and Amgen’s licensing deal with CytomX have been named 2017 “Deals of
the Year.” Clarivate Analytics, the global leader in insights and
analytics that accelerate the pace of innovation, performed a
comprehensive analysis of 4,234 life sciences industry transactions
taking place in 2017 to identify 10 finalists, from which industry
leaders voted to select the top M&A and licensing transactions.
“The winning deals and the other finalists stood apart from more than
4,000 other life sciences deals for their creative structures, use of
novel technology to address unmet medical needs, and their attempts to
penetrate new markets. These factors are what make a ‘good deal’ and
should be the model for the industry,” said Mukhtar Ahmed, President,
Life Sciences at Clarivate Analytics. “The winners also reflect the
broader trends we are seeing where oncology deals represented more than
three times as many deals as neuroscience, the next most prevalent
therapeutic area.”
Bristol-Myers Squibb/IFM Therapeutics
Bristol Myers-Squibb’s (BMS) $2.3 billion acquisition of IFM
Therapeutics, Inc. last year had everything – a young firm, cool
technology and a spinout in the burgeoning cancer sector. BMS is an
industry leader in cancer immunotherapy drugs, and IFM develops
therapies that target the innate immune system, the body’s first line of
immunological response. This focus made two IFM preclinical programs
that work to enhance the immune system's response to cancer cells –
STING and NLRP3 – a natural fit for the BMS oncology portfolio. The deal
included $300 million upfront and $1.01 billion in milestones for the
two programs.
“Bringing in transformational science that complements our portfolio is
at the foundation of our strategy as is developing a ‘win-win’ approach
for both Bristol-Myers Squibb and an outstanding partner like IFM,” said
Paul Biondi, Senior Vice President, Head of Business Development at
Bristol-Myers Squibb. “The acquisition of IFM and subsequent spin out
back to Gary Glick and his talented team is a great example of this
strategy where innovative science is brought together with leading
capabilities and expertise with the central goal of benefiting patients.
Bristol-Myers Squibb is honored to be selected from among thousands of
transactions as a Clarivate Cortellis ‘Deal of the Year.”
“At IFM, we are excited that the acquisition of our oncology portfolio
by Bristol-Myers Squibb has allowed our team to continue research
targeting the innate immune system as a spin-off company, with a goal of
developing transformative medicines for patients living with cancer and
chronic inflammation,” adds Gary D. Glick, Ph.D., President and CEO of
IFM Therapeutics, LLC.
Amgen/CytomX
Amgen’s $1.7 billion immuno-oncology licensing deal with CytomX came on
the heels of CytomX’s $3.6 billion deal with BMS. This time, CytomX’s
creatively-structured discovery stage licensing deal with Amgen included
$40 million in upfront cash and $20 million in equity for the
development of Probody T-cell engaging bispecific antibodies against
EGFRxCD3. CytomX will take the lead on early development, while Amgen
will lead later development and the sales side, should it gain approval,
with global late-stage development costs shared between the two
companies. Probody therapeutics are designed to take advantage of
conditions in the tumor microenvironment to enhance the tumor-targeting
features of an antibody while reducing its impact on healthy tissues,
and thus adverse events.
In addition to identifying the industry’s top transactions, analysis of
the 2017 life sciences deal landscape also revealed that the market
value of the most innovative and impactful life sciences transactions
increased by 6% totaling US $364 billion, while deal volume dropped by
approximately 3%, experiencing contractions in almost every type of deal
structure. This represents a reversal from 2016 when deal volume was up,
but deal dollars were down. The analysis was drawn from Clarivate
Analytics’ Cortellissuite of solutions.
Finalists for the 2017 Clarivate Cortellis “Deal of the Year” included:
M&A
-
BMS/IFM Therapeutics (winner)
-
J&J/Actelion
-
Bioverativ/True North
-
Gilead/Kite
-
Merck/Rigontec
Licensing
-
Amgen/CytomyX (winner)
-
AstraZeneca/Pieris
-
Celgene/BeiGene
-
Eli Lilly/CureVac
-
AbbVie/Alector
About Clarivate Analytics: Clarivate Analytics is the global
leader in providing trusted insights and analytics to accelerate the
pace of innovation. Building on a heritage going back more than a
century and a half, we have built some of the most trusted brands across
the innovation lifecycle, including the Web of Science™, Cortellis™,
Derwent™, CompuMark™, MarkMonitor® and Techstreet™. Today, Clarivate
Analytics is a new and independent company on a bold entrepreneurial
mission, to help our clients radically reduce the time from new ideas to
life-changing innovations. For more information, please visit clarivate.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180307005874/en/
for Clarivate Analytics
Clay Steward, 818-602-2984
csteward@baretzbrunelle.com
Source: Clarivate Analytics